Structure Therapeutics (NASDAQ:GPCR) Upgraded at Lifesci Capital

Key Points

• Structure Therapeutics (NASDAQ:GPCR) has been upgraded to a "strong-buy" rating by Lifesci Capital, reflecting increased positive sentiment among analysts.
• The stock has seen price target adjustments from various analysts, with Guggenheim setting it at $90, while HC Wainwright lowered it to $60 and JMP Securities to $87.
• Currently, Structure Therapeutics has a market capitalization of $1.22 billion and a consensus target price among analysts of $75.71.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) was upgraded by equities researchers at Lifesci Capital to a "strong-buy" rating in a research note issued to investors on Monday, September 8th,Zacks.com reports. Lifesci Capital also issued estimates for Structure Therapeutics' Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.31) EPS and FY2025 earnings at ($1.29) EPS.

A number of other brokerages have also weighed in on GPCR. Guggenheim lowered their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. HC Wainwright lowered their price objective on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, JMP Securities lowered their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $75.71.

Structure Therapeutics Trading Up 0.5%

Shares of NASDAQ GPCR traded up $0.10 during midday trading on Monday, reaching $21.01. 267,528 shares of the company were exchanged, compared to its average volume of 900,258. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $45.37. The stock has a fifty day simple moving average of $18.90 and a 200 day simple moving average of $20.66. The stock has a market cap of $1.21 billion, a P/E ratio of -20.00 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, analysts forecast that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GPCR. State of Wyoming acquired a new position in shares of Structure Therapeutics during the 2nd quarter worth approximately $28,000. GF Fund Management CO. LTD. acquired a new position in shares of Structure Therapeutics during the 4th quarter worth approximately $34,000. National Bank of Canada FI raised its position in shares of Structure Therapeutics by 1,448.2% during the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock worth $51,000 after purchasing an additional 2,766 shares during the last quarter. Assetmark Inc. raised its position in shares of Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company's stock worth $60,000 after purchasing an additional 820 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd raised its position in shares of Structure Therapeutics by 310.7% during the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock worth $74,000 after purchasing an additional 3,213 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.